MVX 008
Vaccine Preventable Diseases
The Phase 3 follow-up study is assessing the ongoing immunogenicity of the GBS vaccine (GBS NN/NN2) previously received by pregnant women between 21-24 weeks gestational age. Our site only participated in the HIV-negative cohort. The study aims to evaluate immunogenicity in these women and offer a booster vaccination to women who become pregnant, with assessments of safety, reactogenicity, and immunogenicity. Enrollment is set to begin in March 2025, with the study concluding in 2029.
Investigators
- Dr Elizea Horne, Principal Investigator
Latest Update
March 2025
For more details about MVX 008, please email rhicomms@wrhi.ac.za.
